These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30032236)

  • 1. Pneumococcal Conjugate Vaccines Turning the Tide on Inequity: A Retrospective Cohort Study of New Zealand Children Born 2006-2015.
    Petousis-Harris H; Howe AS; Paynter J; Turner N; Griffin J
    Clin Infect Dis; 2019 Feb; 68(5):818-826. PubMed ID: 30032236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective cohort study investigating the comparative effectiveness of pneumococcal vaccines against hospitalisation with otitis media and pneumonia in New Zealand.
    Paynter J; Howe AS; Best E; Petousis-Harris H
    Vaccine; 2023 Jun; 41(28):4121-4128. PubMed ID: 37244807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada.
    Deceuninck G; De Serres G; Boulianne N; Lefebvre B; De Wals P
    Vaccine; 2015 May; 33(23):2684-9. PubMed ID: 25887086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Vaccine Impact on Invasive Pneumococcal Disease Among Children With Significant Comorbidities in a Large Australian Birth Cohort.
    Jayasinghe S; Liu B; Gidding H; Gibson A; Chiu C; McIntyre P
    Pediatr Infect Dis J; 2019 Sep; 38(9):967-973. PubMed ID: 31408056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in the Nature and Severity of Invasive Pneumococcal Disease in Children Before and After the Seven-valent and Thirteen-valent Pneumococcal Conjugate Vaccine Programs in Calgary, Canada.
    Ricketson LJ; Conradi NG; Vanderkooi OG; Kellner JD
    Pediatr Infect Dis J; 2018 Jan; 37(1):22-27. PubMed ID: 28737622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies.
    Ben-Shimol S; Givon-Lavi N; Grisaru-Soen G; Megged O; Greenberg D; Dagan R;
    Vaccine; 2018 Aug; 36(36):5477-5484. PubMed ID: 28579230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland.
    Rinta-Kokko H; Palmu AA; Auranen K; Nuorti JP; Toropainen M; Siira L; Virtanen MJ; Nohynek H; Jokinen J
    Vaccine; 2018 Apr; 36(15):1934-1940. PubMed ID: 29526371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethnic differences in acute hospitalisations for otitis media and elective hospitalisations for ventilation tubes in New Zealand children aged 0-14 years.
    McCallum J; Craig L; Whittaker I; Baxter J
    N Z Med J; 2015 Jun; 128(1416):10-20. PubMed ID: 26117671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.
    Farnham AC; Zimmerman CM; Papadouka V; Konty KJ; Zucker JR; Nattanmai GV; Jose S; Rosen JB
    JAMA Pediatr; 2015 Jul; 169(7):646-52. PubMed ID: 25938798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
    Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB;
    Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand.
    Varghese L; Talbot L; Govender A; Zhang XH; Mungall BA
    Appl Health Econ Health Policy; 2018 Jun; 16(3):331-345. PubMed ID: 29633160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sinusitis and pneumonia hospitalization after introduction of pneumococcal conjugate vaccine.
    Lindstrand A; Bennet R; Galanis I; Blennow M; Ask LS; Dennison SH; Rinder MR; Eriksson M; Henriques-Normark B; Ortqvist A; Alfvén T
    Pediatrics; 2014 Dec; 134(6):e1528-36. PubMed ID: 25384486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the effectiveness of pneumococcal conjugate vaccine for children in Korea with high vaccine coverage using a propensity score matched national population cohort.
    Sohn S; Hong K; Chun BC
    Int J Infect Dis; 2020 Apr; 93():146-150. PubMed ID: 31982620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric invasive pneumococcal disease in Taiwan following a national catch-up program with the 13-valent pneumococcal conjugate vaccine.
    Wei SH; Chiang CS; Chiu CH; Chou P; Lin TY
    Pediatr Infect Dis J; 2015 Mar; 34(3):e71-7. PubMed ID: 25247584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the impact of PCV-10 on invasive pneumococcal disease in Brazil: A time-series analysis.
    Andrade AL; Minamisava R; Policena G; Cristo EB; Domingues CM; de Cunto Brandileone MC; Almeida SC; Toscano CM; Bierrenbach AL
    Hum Vaccin Immunother; 2016; 12(2):285-92. PubMed ID: 26905679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumococcal Conjugate Vaccine and Clinically Suspected Invasive Pneumococcal Disease.
    Palmu AA; Kilpi TM; Rinta-Kokko H; Nohynek H; Toropainen M; Nuorti JP; Jokinen J
    Pediatrics; 2015 Jul; 136(1):e22-7. PubMed ID: 26077477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Pneumococcal Vaccination on Pneumonia Hospitalizations and Related Costs in Ontario: A Population-Based Ecological Study.
    Luca DL; Kwong JC; Chu A; Sander B; O'Reilly R; McGeer AJ; Bloom DE
    Clin Infect Dis; 2018 Feb; 66(4):541-547. PubMed ID: 29029063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Pneumococcal Conjugate Universal Routine Vaccination on Pneumococcal Disease in Italian Children.
    Fortunato F; Martinelli D; Cappelli MG; Cozza V; Prato R
    J Immunol Res; 2015; 2015():206757. PubMed ID: 26351644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of infant pneumococcal conjugate vaccination on community acquired pneumonia hospitalization in all ages in the Netherlands.
    van Deursen AMM; Schurink-Van't Klooster TM; Man WH; van de Kassteele J; van Gageldonk-Lafeber AB; Bruijning-Verhagen PCJL; de Melker HE; Sanders EAM; Knol MJ
    Vaccine; 2017 Dec; 35(51):7107-7113. PubMed ID: 29146381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.